Physician profile
Scott B Halperin
NPI 1972546612
$10,079.08
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $2,000 · 2021: $2,183 · 2022: $1,429 · 2023: $1,520 · 2024: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.57 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,442.01 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,138.27 | 2019-2024 | |
| Lilly USA, LLC | $900.66 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $670.96 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $623.59 | 2019-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $604.96 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $523.56 | 2019-2024 | |
| Allergan, INC. | $517.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $492.22 | 2019-2024 | Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $390.06 | 2019-2024 | Ztlido |
| Radius Health, INC. | $347.08 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $257.25 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $241.51 | 2019-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $149.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $148.73 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Halperin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.